Tadilecto
Poland
Table of Contents
Package leaflet: Information for the patient
Tadilecto, 10 mg, coated tablets
Tadalafilum
Please read all of this leaflet carefully before taking the medicine, as it contains
important information for the patient.
- Keep this leaflet, as you may need to read it again.
- If you have any further questions, please consult your doctor or pharmacist.
- This medicine has been prescribed for a specific individual. Do not pass it on to others. The medicine may harm others, even if their symptoms are the same.
- If you experience any adverse reactions, including any not listed in this leaflet, inform your doctor or pharmacist. See section 4.
Table of contents
- What Tadilecto is and what it is used for
- Important information before taking Tadilecto
- How to take Tadilecto
- Possible side effects
- How to store Tadilecto
- Contents of the pack and other information
1. What Tadilecto is and what it is used for
Tadilecto is a medicine intended for adult men with erectile dysfunction. This is a condition
in which a man is unable to achieve or maintain an erection sufficient for sexual intercourse.
Tadilecto has been shown to significantly improve the ability to achieve an erection adequate for sexual intercourse.
Tadilecto contains the active substance tadalafil, which belongs to a group of medicines called phosphodiesterase type 5 inhibitors.
During sexual stimulation, Tadilecto helps widen the blood vessels of the penis, allowing increased blood flow into the penis. As a result, erection improves. Tadilecto does not benefit patients who do not have erectile dysfunction.
It is important to be aware that Tadilecto does not work in the absence of sexual stimulation.
The patient should engage in foreplay, just as when not taking medication for erectile dysfunction.
2. Important information before using Tadilecto
When not to use Tadilecto
- if the patient is allergic to tadalafil or any of the other ingredients of this medicine (listed in section 6),
- if the patient is taking organic nitrates in any form or other nitric oxide donors, e.g. amyl nitrite. This is a group of medicines ("nitrates") used to treat angina (chest pain). It has been shown that tadalafil enhances the effects of these medicines. If the patient is taking nitrates in any form or is unsure, they should inform their doctor.
- if the patient has severe heart disease or has had a heart attack within the last 90 days,
- if the patient has had a stroke within the last 6 months,
- if the patient has low blood pressure or uncontrolled high blood pressure,
- if the patient has ever experienced vision loss due to non-arteritic anterior ischemic optic neuropathy (NAION), also known as "eye stroke",
- if the patient is taking riociguat. This is a medicine used to treat pulmonary hypertension (i.e. high blood pressure in the lungs) and chronic thromboembolic pulmonary hypertension (i.e. high blood pressure in the lungs caused by blood clots). PDE5 inhibitors, such as tadalafil, have been shown to enhance the blood pressure-lowering effect of this medicine. If the patient is taking riociguat or is unsure, they should inform their doctor.
Warnings and precautions
Before starting Tadilecto, consult a doctor or pharmacist.
Please remember that sexual activity involves some risk for patients with heart disease, as it places additional strain on the heart. If the patient has any heart problems, they should inform their doctor.
Before taking this medicine, the patient should inform their doctor if any of the following apply:
- sickle cell anemia (abnormally shaped red blood cells),
- multiple myeloma (a bone marrow cancer),
- leukemia (a blood cell cancer),
- any deformity of the penis,
- severe liver disease,
- severe kidney disease.
It is not known whether Tadilecto is effective in patients:
- after pelvic surgery,
- after complete or partial removal of the prostate gland with nerve-sparing techniques (nerve-sparing radical prostatectomy).
If sudden vision deterioration or sudden vision loss occurs, or if vision becomes distorted or blurred, stop taking Tadilecto and contact a doctor immediately.
In some patients taking tadalafil, worsening or sudden hearing loss has been observed.
Although it is not known whether this event is directly related to the use of tadalafil, if hearing deterioration or sudden hearing loss occurs, stop taking Tadilecto and contact a doctor immediately.
Tadilecto is not intended for use in women.
Children and adolescents
Tadilecto is not intended for use in children and adolescents under 18 years of age.
Tadilecto and other medicines
Tell your doctor about all medicines currently taken or taken recently, as well as any medicines the patient plans to take.
DO NOT take Tadilecto if you are using nitrates.
Tadilecto may affect the action of certain medicines, or other medicines may affect the action of Tadilecto. Tell your doctor or pharmacist if you are taking any of the following medicines:
- alpha-adrenergic receptor blockers (used to treat high blood pressure or urinary symptoms caused by benign prostatic hyperplasia),
- other medicines used to treat high blood pressure,
- riociguat (a medicine used to treat certain types of pulmonary arterial hypertension),
- 5-alpha-reductase inhibitors (medicines used to treat benign prostatic hyperplasia),
- medicines such as oral ketoconazole (used to treat fungal infections) and protease inhibitors used to treat AIDS or HIV infection,
- phenobarbital, phenytoin, and carbamazepine (anticonvulsant medicines),
- rifampicin, erythromycin, clarithromycin, or itraconazole,
- other medicines used to treat erectile dysfunction.
Tadilecto, food, and alcohol
Information regarding the effect of alcohol is provided in section 3.
Grapefruit juice may affect the effectiveness of Tadilecto, and therefore caution should be exercised when consuming it. For further information, consult a doctor.
Effect on fertility
When tadalafil was administered to dogs, a reduction in sperm production in the testes was observed.
Reduced sperm concentration has been observed in some men. It is unlikely that this would lead to infertility.
Driving and operating machinery
Some men using tadalafil in clinical trials reported dizziness. Therefore, patients should understand their response to the medicine before deciding to drive or operate machinery.
Tadilecto contains lactose and sodium
If the patient has previously been diagnosed with intolerance to certain sugars, they should consult their doctor before taking this medicine.
The medicine contains less than 1 mmol (23 mg) of sodium per tablet; therefore, the medicine is considered "sodium-free".
3. How to use Tadilecto
This medicine should always be taken as directed by a doctor or pharmacist. If in
doubt, consult a doctor or pharmacist.
Tadilecto tablets are intended for oral administration only in men. The tablets should be
swallowed whole, with a small amount of water. Tadilecto tablets may be taken regardless of
meals.
The recommended starting dose is 10 mg, taken prior to planned sexual activity. If
this dose is not sufficient, the doctor may increase the dose to 20 mg.
Tadilecto may be taken at least 30 minutes before planned sexual activity.
Tadilecto may still be effective up to 36 hours after taking the tablet.
Tadilecto should not be taken more than once a day.
Tadilecto 10 mg and 20 mg is intended for use prior to planned sexual activity. Regular, daily
use of the medicine is not recommended.
It is important to be aware that Tadilecto does not work in the absence of sexual stimulation.
The patient should engage in foreplay, just as when not using erectile dysfunction medicines.
Alcohol consumption may affect the patient's ability to achieve an erection and may cause
transient lowering of blood pressure. If the patient has taken or plans to take Tadilecto, he should
not consume large amounts of alcohol (blood alcohol concentration of 0.08% or higher), as this
may increase the risk of dizziness upon standing.
Use of a higher than recommended dose of Tadilecto
Inform the doctor immediately. Adverse effects described in section 4 may occur.
If there are any further doubts regarding the use of this medicine, consult a doctor or pharmacist.
4. Possible adverse reactions
Like all medicines, this medicine can cause adverse reactions, although not everybody gets them.
These reactions are usually mild or moderate.
If any of the adverse reactions listed below occur, stop taking the medicine
and seek medical advice immediately:
- allergic reactions, including rashes (uncommon),
- chest pain – do not take nitrates, but seek immediate medical help (uncommon),
- priapism: prolonged and possibly painful erection after taking Tadilecto (rare). If such an erection occurs and lasts continuously for more than 4 hours, contact a doctor immediately,
- sudden loss of vision (rare), distorted, dimmed, blurred central vision or sudden worsening of vision (frequency not known).
Other reported adverse reactions:
Common (may occur in up to 1 in 10 patients):
- headache, back pain, muscle pain, pain in arms and legs, facial flushing, nasal mucosa congestion and indigestion.
Uncommon (may occur in up to 1 in 100 patients):
- dizziness, abdominal pain, gastroesophageal reflux, nausea, vomiting, blurred vision, eye pain, difficulty breathing, presence of blood in urine, prolonged erection, palpitations, rapid heartbeat, high blood pressure, low blood pressure, nosebleeds, tinnitus, swelling of hands, feet or ankles and feeling of fatigue.
Rare (may occur in up to 1 in 1,000 patients):
- fainting, convulsions and transient memory loss, eyelid swelling, eye redness, sudden worsening or loss of hearing, urticaria (itchy, red skin eruptions), increased sweating, rectal bleeding and presence of blood in semen.
Heart attack and stroke have been rarely reported in men taking tadalafil. Most of these men had
heart problems before starting tadalafil treatment.
There have been reports of rare cases of partial, transient or permanent
visual impairment or vision loss in one or both eyes.
In men taking tadalafil, a few additional rare adverse reactions have been reported
which were not observed during clinical trials. These include:
- migraine, facial swelling, severe allergic reactions causing facial and throat swelling, severe skin rashes, disorders characterized by blood rush to the eyes, irregular heartbeat, angina pectoris, and sudden cardiac death.
- distorted, dimmed, blurred central vision or sudden worsening of vision (frequency not known).
Adverse reaction: dizziness was reported more frequently in men over 75 years of age
taking tadalafil. Diarrhea was reported more frequently in men over 65 years of age
taking tadalafil.
Reporting of adverse reactions
If any adverse symptoms occur, including any adverse symptoms not listed
in this leaflet, inform your doctor or pharmacist. Adverse reactions can
be reported directly to the Department of Monitoring Adverse Reactions of Medicinal Products at the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products:
Al. Jerozolimskie 181C, 02-222 Warsaw
tel.: + 48 22 49-21-301
fax: + 48 22 49-21-309
Website: https://smz.ezdrowie.gov.pl
Adverse reactions can also be reported to the marketing authorization holder.
Reporting adverse reactions helps to provide more information on the safety of the medicine.
5. How to store Tadilecto
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the stated month.
No special storage instructions are required for this medicine.
Medicines must not be disposed of via the sewage system or household waste. Ask your pharmacist how to dispose of medicines no longer in use. Such measures will help protect the environment.
6. Contents of the packaging and other information
What Tadilecto contains
- The active substance is tadalafil. Each coated tablet contains 10 mg of tadalafil.
- The other ingredients are: hypromellose phthalate, mannitol, sodium croscarmellose, sodium lauryl sulfate, magnesium stearate in the tablet core; monohydrate lactose, hypromellose 6 cP, talc, titanium dioxide (E 171), yellow iron oxide (E 172), and triacetin in the tablet coating. See section 2 "Tadilecto contains lactose and sodium".
What Tadilecto looks like and contents of the pack
Tadilecto 10 mg, coated tablets (tablets): yellow, oval, biconvex tablets with the marking "10" on one side. Tablet dimensions: approximately 12 mm in length and 7.5 mm in width.
Packaging: 2, 4, 8, 12, 14, 28, 56 and 84 coated tablets in blister packs contained in a cardboard box.
Not all pack sizes may be marketed.
Marketing Authorisation Holder and Manufacturer
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
For further information on the names of the medicinal products in other European Economic Area countries, please contact the representative of the Marketing Authorisation Holder:
KRKA-POLSKA Sp. z o.o.
Równoległa 5 Street
02-235 Warsaw, Poland
Tel. 22 57 37 500